• Saved

May 04, 2021

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era

Source : https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2869

​ORIGINAL RESEARCH ARTICLE Corresponding Author Departments of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, the Sino‐US Center for Lymphoma and Leukemia Research, Tianjin, China Correspondence Huilai Zhang and Xianhuo Wang, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, Tianjin, China.

  • May 04, 2021
    This data is consistent with most reports in the rituxan era of the limited value of xrt for most cases of limited stage dlbcl treated with immunochemotherapy